DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Sacral Nerve Stimulation Market 2017-2021" report to their offering. The global sacral nerve stimulation market ...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc., the developer of the first rechargeable Sacral Neuromodulation (r-SNM™) System for the treatment of urinary and fecal ...
The battery-free percutaneous sacral neuromodulation system has comparable efficacy to published rates for traditional sacral neuromodulation devices. The US Food and Drug Administration (FDA) has ...
Fewer punctures and shorter surgical time reported for sacral neuromodulation with 3D printing and ultrasound localization. (HealthDay News) — For patients with neurogenic bladder and pelvic ...
Axonics Inc. received FDA approval for its recharge-free sacral neuromodulation (SNM) implantable neurostimulator (INS) for bladder and bowel dysfunction. The F15’s primary cell requires no recharging ...
Axonics (NASDAQ:AXNX) said it acquired a lead placement solution from Radian which complements the company's existing sacral neuromodulation (SNM) offering. The company acquired the assets of Radian ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results